First-in-Human cell therapy trial targets Tough-to-Treat brain autoimmune disorders
NCT ID NCT07021209
Summary
This is an early-stage study to test the safety and initial effects of a new cell therapy called GT719. It is for adults with neurological autoimmune diseases that have come back or not improved with standard treatments. Researchers will give participants an infusion of GT719 cells and closely monitor them for side effects and how the cells behave in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROLOGICAL AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.